dc.contributor.author | Poyraz, Mehmet | |
dc.contributor.author | Berber, Halil | |
dc.contributor.author | Banti, Christina N. | |
dc.contributor.author | Kourkoumelis, Nikolaos | |
dc.contributor.author | Manos, Manolis J. | |
dc.contributor.author | Hadjikakou, Sotiris K. | |
dc.date.accessioned | 2019-10-20T09:02:57Z | |
dc.date.available | 2019-10-20T09:02:57Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 0277-5387 | |
dc.identifier.uri | https://dx.doi.org/10.1016/j.poly.2017.03.011 | |
dc.identifier.uri | https://hdl.handle.net/11421/16576 | |
dc.description | WOS: 000401047100012 | en_US |
dc.description.abstract | The treatment with triphenylphosphine (TPP) in DMF solution of the white precipitation derived from the reaction of silver(I) nitrate with 2-benzimidazolylurea (BZIMU) results in the [Ag(TPP)(2)(BZIMU)NO3] (1) complex. The product was characterized by elemental analysis and spectroscopic techniques (FT-IR and H-1, C-13 NMR). Single crystal X-ray diffraction analysis of 1 have been carried out at 293 K. Mixed ligand complexes of silver(I) nitrate with urea derivatives and phosphines which exhibits significant biological effects are rare in the literature. Complex 1 was evaluated for its in vitro cytotoxic activity (cell viability) against: (i) human breast adenocarcinoma cancer cell line (MCF-7) and (ii) normal human fetal lung fibroblast cells (MRC-5) with SRB assay. The results showed that 1 mediates a strong cytotoxic response to the tested normal (MRC-5) and cancer cell lines (MCF-7). It is also exhibits four time stronger activity against cancer cells (MCF-7) than cisplatin while it is less toxic against normal cells (MRC-5). The therapeutic potency index (TPI) which is define as the IC50 value of 1 against normal cells divided by its IC50 value against cancerous cells is 0.9 in contrast to the 0.2 of cisplatin. The influence of the complex 1, upon the catalytic peroxidation of linoleic acid to hydroperoxylinoleic acid by the enzyme lipoxygenase (LOX) was kinetically and theoretically studied | en_US |
dc.description.sponsorship | Oncology Department of Novartis Hellas S.A.C.I. [81939] | en_US |
dc.description.sponsorship | The authors acknowledge Scientific and Technological Research Application and Research Center, Sinop University, Turkey, for the use of the Bruker D8 QUEST diffractometer. The Unit of Bioactivity Testing of Xenobiotics, of the University of Ioannina-Greece, is also acknowledge for providing access to the facilities. SKIT acknowledge the Oncology Department of Novartis Hellas S.A.C.I. for the financial support (project number: 81939) | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Pergamon-Elsevier Science LTD | en_US |
dc.relation.isversionof | 10.1016/j.poly.2017.03.011 | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Biological Inorganic Chemistry | en_US |
dc.subject | Silver(I) Metallo-Drugs | en_US |
dc.subject | Urea Derivative | en_US |
dc.subject | Cells Screening | en_US |
dc.subject | Crystal Structure | en_US |
dc.title | Synthesis characterization and biological activity of mixed ligand silver(I) complex of 2-benzimidazolylurea and triphenylphosphine | en_US |
dc.type | article | en_US |
dc.relation.journal | Polyhedron | en_US |
dc.contributor.department | Anadolu Üniversitesi, Fen Fakültesi, Fizik Bölümü | en_US |
dc.identifier.volume | 128 | en_US |
dc.identifier.startpage | 95 | en_US |
dc.identifier.endpage | 103 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.contributor.institutionauthor | Berber, Halil | |